Table 6. Suggestions for Novel Oral Anticoagulation Discontinuation Prior to Planned Surgical Intervention^46,47^*

Creatinine Clearance (mL/min)	Dabigatran		Rivaroxaban		Apixaban
Creatinine Clearance (mL/min)	Low Risk	High Risk	Low Risk	High Risk	Low Risk	High Risk
>50	≥2 Days	≥3 Days	≥2 Days	≥3 Days	≥2 Days	≥3 Days
30–50	≥3 Days	≥4 to 5 Days	≥2 Days	≥3 Days	≥3 Days	≥4-5 Days
15–30	Not indicated	Not indicated	≥3 Days	≥4 Days	Not indicated	Not indicated
<15	No official indication for use

↵* No important bleeding risk and/or adequate local hemostasis possible. Perform at trough level (ie, ≥12 hours or 24 hours after last intake).